Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Arcamone · SciRah

Researcher profile · Semantic Scholar

M. Arcamone

Share profile

M. Arcamone — researcher profile on SciRah

h-index: 13
Works: 42
Citations: 629

Most-cited papers

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
C. Scholz, A. Pinto, W. Linkesch, Ola Lindén +11 more
2013Journal of Clinical Oncology93 citations Open access
Semantic Scholar
RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma
G. Corazzelli, F. Frigeri, F. Russo, C. Frairia +12 more
2012British Journal of Haematology83 citations Open access
Semantic Scholar
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
G. Corazzelli, G. Capobianco, M. Arcamone, Pier Ferruccio Ballerini +7 more
2009Cancer Chemotherapy and Pharmacology82 citations
Semantic Scholar
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
G. Corazzelli, F. Angrilli, A. D'Arco, F. Ferrara +12 more
2013British Journal of Haematology64 citations Open access
Semantic Scholar
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high ‘life threat’ impact cardiopathy
G. Corazzelli, F. Frigeri, M. Arcamone, A. Lucania +12 more
2011British Journal of Haematology55 citations Open access
Semantic Scholar
Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma
G. Corazzelli, R. De Filippi, G. Capobianco, F. Frigeri +10 more
2009American journal of hematology/oncology34 citations Open access
Semantic Scholar
To the editor : Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection ?
Ferdinando Frigeri, M. Arcamone, L. Luciano, R. Di Francia +1 more
200926 citations
Semantic Scholar
DMSO-associated encephalopathy during autologous peripheral stem cell infusion: a predisposing role of preconditioning exposure to CNS-penetrating agents?
G. Marcacci, G. Corazzelli, C. Becchimanzi, M. Arcamone +4 more
2009Bone Marrow Transplantation19 citations Open access
Semantic Scholar
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
S. Palmieri, S. Rocco, O. Vitagliano, L. Catalano +16 more
2020Annals of Hematology17 citations
Semantic Scholar
Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma
D. Galati, S. Zanotta, G. Corazzelli, D. Bruzzese +5 more
2018British Journal of Haematology17 citations
Semantic Scholar
Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial.
G. Corazzelli, F. Frigeri, G. Marcacci, C. Becchimanzi +6 more
201016 citations
Semantic Scholar
Elevation of clonal serum free light chains in patients with HIV‐negative primary effusion lymphoma (PEL) and PEL‐like lymphoma
R. De Filippi, Giancarla Iaccarino, F. Frigeri, R. Di Francia +8 more
2009British Journal of Haematology16 citations
Semantic Scholar
To the editor: Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome–positive leukemia
M. Arcamone, A. Pinto
200914 citations
Semantic Scholar
Abnormally Elevated Levels of Serum Free-Immunoglobulin Light Chains Are Frequently Found in Classic Hodgkin Lymphoma (cHL) and Predict Outcome of Patients with Early Stage Disease.
R. De Filippi, F. Russo, Giancarla Iaccarino, S. Crisci +13 more
200912 citations
Semantic Scholar
90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial
C. Scholz, A. Pinto, W. Linkesch, Ola Lindén +9 more
201010 citations
Semantic Scholar
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
D. De Novellis, D. Derudas, D. Vincelli, R. Fontana +45 more
2024European Journal of Haematology9 citations Open access
Semantic Scholar
Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma.
G. Corazzelli, Ferdinando Frigeri, G. Marcacci, G. Capobianco +4 more
2009Journal of Clinical Oncology9 citations
Semantic Scholar
Erratum to: Multidisciplinary approach and anesthetic management of a surgical cancer patient with methylene tetrahydrofolate reductase deficiency: a case report and review of the literature
M. Cascella, M. Arcamone, E. Morelli, D. Viscardi +13 more
2015Journal of Medical Case Reports8 citations Open access
Semantic Scholar
Multidisciplinary approach and anesthetic management of a surgical cancer patient with methylene tetrahydrofolate reductase deficiency: a case report and review of the literature
M. Cascella, M. Arcamone, E. Morelli, D. Viscardi +13 more
2015Journal of Medical Case Reports6 citations Open access
Semantic Scholar
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
A. Pinto, G. Corazzelli, A. Evangelista, C. Patti +37 more
2023Hematological Oncology5 citations Open access
Semantic Scholar
Fatal Outcome of COVID-19 Relapse in a Fully Vaccinated Patient with Non-Hodgkin Lymphoma Receiving Maintenance Therapy with the Anti-CD20 Monoclonal Antibody Obinutuzumab: A Case Report
Federica Calò, Lorenzo Onorato, M. Pisaturo, A. Pinto +8 more
2022Vaccines4 citations Open access
Semantic Scholar
Lenalidomide in Combination with Bendamustine for Patients with Chemorefractory Hodgkin Lymphoma: Final Results of the Leben Multicenter Phase 1/2 Study
A. Pinto, V. Pavone, F. Angrilli, M. Saggese +15 more
20154 citations
Semantic Scholar
Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma.
L. Aloj, L. D'Ambrosio, Michela Aurilio, R. Marreno +9 more
2011Journal of Clinical Oncology4 citations
Semantic Scholar
Long‐term efficacy and safety of dose‐dense and dose‐intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15‐year follow‐up of the ABVDDD‐DI phase II study
G. Corazzelli, Annarosa Cuccaro, E. Morelli, M. Arcamone +14 more
2024British Journal of Haematology3 citations Open access
Semantic Scholar
A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma.
G. Corazzelli, M. Saggese, V. Pavone, F. Angrilli +11 more
20143 citations
Semantic Scholar
Dose-Dense(dd) ABVD and Dose-Dense/Dose-Intense(dd-di) ABVD in Newly Diagnosed Patients (pts), Intermediate- and Advanced-Stage with Classical Hodgkin's Lymphoma (cHL): Final Results.
F. Russo, G. Corazzelli, S. Lastoria, G. Marcacci +5 more
20093 citations
Semantic Scholar
The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones
R. De Filippi, S. Crisci, M. Cillo, S. Mele +12 more
20152 citations
Semantic Scholar
Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan
C. Arrichiello, L. Aloj, M. Mormile, L. D'Ambrosio +6 more
2012European Journal of Nuclear Medicine and Molecular Imaging2 citations
Semantic Scholar
Single Vs Double Dose Palonosetron For The Prevention Of Acute And Delayed Nausea And Vomiting In Patients Undergoing High Dose Chemotherapy And Autologous Stem Cell Transplantation
G. Marcacci, C. Becchimanzi, G. Capobianco, M. Arcamone +4 more
20102 citations Open access
Semantic Scholar
9249 Single vs double dose palonosetron for the prevention of acute and delayed nausea and vomiting in patients undergoing high dose chemotherapy and autologous stem cell transplantation
G. Marcacci, C. Becchimanzi, M. Arcamone, G. Capobianco +4 more
20092 citations
Semantic Scholar
Rituximab Plus Gemcitabine, Ifosfamide, Oxaliplatin (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Hodgkin Lymphoma
G. Corazzelli, G. Capobianco, M. Arcamone, C. Becchimanzi +4 more
20082 citations
Semantic Scholar
Dose- and time-intensified ABVD without radiotherapy (RT) for advanced-stage Hodgkin lymphoma (HL) with mediastinal bulky disease (MBD).
G. Corazzelli, F. Russo, F. Frigeri, F. Volzone +8 more
20121 citations
Semantic Scholar
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
G. Corazzelli, F. Frigeri, M. Arcamone, L. Aloj +9 more
2011European Journal of Haematology1 citations Open access
Semantic Scholar
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies
D. De Novellis, S. Palmieri, Stefano Rocco, D. Derudas +36 more
2025Annals of Hematology0 citations Open access
Semantic Scholar
EXTENDED BRENTUXIMAB VEDOTIN LEAD‐IN AND ABBREVIATED AVD IN OLDER PATIENTS (> 60 YEARS) WITH ADVANCED HODGKIN LYMPHOMA AND HIGH COMORBIDITY (ECOG ≥ 2 AND/OR CIRS‐G > 10)
M. Bonanni, A. Cuccaro, S. Mele, E. Morelli +12 more
2025Hematological Oncology0 citations Open access
Semantic Scholar
Molecular Determinants of Bendamustine (BDM) Toxicity towards Hodgkin (H) and Reed-Sternberg (RS) Cell Lines From Hodgkin Lymphoma (HL).
R. De Filippi, S. Crisci, F. Frigeri, D. Aldinucci +10 more
20120 citations
Semantic Scholar
A phase II study of R-COMP14 in elderly patients with high-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high "life threat" impact cardiopathy.
G. Corazzelli, Ferdinando Frigeri, M. Arcamone, Anna Lucania +10 more
2011Journal of Clinical Oncology0 citations
Semantic Scholar
Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.
F. Frigeri, G. Corazzelli, M. Arcamone, G. Capobianco +7 more
20090 citations
Semantic Scholar
Safety and Efficacy of Intrathecal Liposome-Encapsulated Cytarabine for Central Nervous System (CNS) Prophylaxis in Adult Patients with Burkitt and Atypical Burkitt Lymphoma Treated with the R-CODOX-M/R-IVAC (Magrath) Regimen: Results of a Phase II Study.
F. Frigeri, F. Russo, M. Arcamone, Chiara Fraira +10 more
20090 citations
Semantic Scholar
Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Ferdinando Frigeri, M. Arcamone, L. Luciano, R. Di Francia +2 more
2009Blood0 citations
Semantic Scholar
A412 Serum Free-Immunoglobulin Light Chains Testing Is Frequently Abnormal in Patients with B-Cell Non-Hodgkin and Hodgkin Lymphoma and May Change in Value for Prognosis and Therapeutic Monitoring
R. De Filippi, Giancarla Iaccarino, F. Frigeri, F. Russo +7 more
20090 citations
Semantic Scholar
CORRELATIONS BETWEEN ELEVATED SERUM FERRITINE LEVEL AND INITIAL CHARACTERISTICS OF HODGKIN ’ S LYMPHOMA PATIENTS
S. Capria, N. Frattarelli, A. Matturro, F. De Angelis +27 more
20080 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Corazzelli×27
Invite
G. Corazzelli — researcher profile on SciRah
F. Frigeri×25
Invite
F. Frigeri — researcher profile on SciRah
G. Capobianco×23
Invite
G. Capobianco — researcher profile on SciRah
A. Pinto×21
Invite
A. Pinto — researcher profile on SciRah

×19

Invite

R. De Filippi — researcher profile on SciRah

Invite

F. Russo — researcher profile on SciRah

C. Becchimanzi×17

Invite

C. Becchimanzi — researcher profile on SciRah

G. Marcacci×16

Invite

G. Marcacci — researcher profile on SciRah

Invite

E. Morelli — researcher profile on SciRah

Invite

A. Pinto — researcher profile on SciRah

Invite

S. Crisci — researcher profile on SciRah

Invite

F. Volzone — researcher profile on SciRah